SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
To our Shareholders:
The purpose of this letter is to summarize our progress to date in 2007 and to outline our plan to finance operations over the next 24 months. During the course of the year, we significantly advanced our mission to establish the industry for medical devices capable of treating infectious disease. Specifically, we initiated and progressed seven collaborations with researchers representing both government and non-government health organizations. Without having to grant either rights or ownership of our Hemopurifier®, we successfully leveraged these collaborations to further demonstrate the utility of the Hemopurifer® as a potential treatment countermeasure against bioterror, pandemic, and chronic infectious disease threats.
